Global & Regional Health Technology Assessment: Italian;Northern Europe and Spanish: Sage Journals

Global & Regional Health Technology Assessment: Italian;Northern Europe and Spanish journal cover

Global and Regional Health Technology Assessment, is an international, peer-reviewed, open access journal focusing on promoting health technology assessment and economic evaluation, enabling choices among alternative therapeutical paths or procedures with different clinical and economic outcomes. Please see the Aims and Scope tab for further information. This journal is a member of the Committee o...|View full journal description

Browse by

Articles most recently published online for this journal.

Open accessResearch articleFirst published 2019
Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy
Roberto RavasioORCIDSilvia AntonelliAlessia Maiorino
View All
Open accessResearch articleFirst published 2019
The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri ® PharmacoEconomics (TyPE) Study
B PolistenaORCIDF SpandonaroR Capra
View All
Open accessResearch articleFirst published 2019
Determining the value contribution of emicizumab (Hemlibra ® ) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Maria Teresa Álvarez-RománIgnacio Cuervo-ArangoRafael Pérez-Santamarina
View All
Open accessResearch articleFirst published 2019
Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses
Nicola Amedeo MazzantiCarolina ScauriBianca DominiORCID
View All

View All

Browse by

Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy

The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri ® PharmacoEconomics (TyPE) Study

Determining the value contribution of emicizumab (Hemlibra ® ) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses